

# Viral Epidemiology Snapshot: April 10-16, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

## CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	614	143	23.3%
Flu B	614	2	0.3%
RSV	252	4	1.6%
CoV-2 PUI	754	53	7.0%
CoV-2 Surveillance	453	0	0.0%


## Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	33
No Subtype	110
Pending subtype	0

## Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	249	19	7.6%
Coronavirus 229E	249	7	2.8%
Coronavirus HKU1	249	1	0.4%
Coronavirus NL63	249	7	2.8%
Coronavirus OC43	249	14	5.6%
Metapneumovirus	249	15	6.0%
Rhinovirus/Enterovirus	249	66	26.5%
Parainfluenza 1	249	0	0.0%
Parainfluenza 2	249	0	0.0%
Parainfluenza 3	249	6	2.4%
Parainfluenza 4	249	0	0.0%

## Flu, RSV, & CoV-2 Trends



This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/20) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

## CoV-2 Positivity Rate Trends

